Form 4: Artiva CMO Granted 102,000 Restricted Stock Units

Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, was granted 102,000 restricted stock units under the company's 2024 Equity Incentive Plan.

Summary

• Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, Inc. (ARTV), was granted 102,000 shares of common stock.
• This grant represents a restricted stock unit (RSU) award under the company's 2024 Equity Incentive Plan.
• The transaction date for this acquisition is February 15, 2026.
• Following this transaction, Banerjee will beneficially own 152,000 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests, though it doesn't indicate new operational performance.

Positives

• The grant of 102,000 restricted stock units to the Chief Medical Officer aligns management incentives with shareholder interests.
• The award is part of the company's 2024 Equity Incentive Plan, indicating an ongoing commitment to executive compensation and retention.

Future Outlook

The transaction date of February 15, 2026, indicates a pre-planned equity award that will vest or be granted in the future, aligning executive compensation with future company performance.

Industry Context

StockSavvy.ai notes that equity grants are a standard practice in the biotechnology industry to attract, retain, and incentivize key executives, aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity incentive plans and RSU grants are common compensation tools across the biotech sector.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize similar equity-based compensation structures for their executive teams to foster innovation and drive pipeline development.

Corporate Governance

Related Party Transactions

• Grant of 102,000 restricted stock units to Chief Medical Officer Subhashis Banerjee under the company's 2024 Equity Incentive Plan, representing a standard compensation arrangement between an officer and the company.

Stakeholder Impact

• Shareholders: Potential positive impact through improved management alignment and retention, but also potential future dilution from new share issuance upon vesting.
• Employees: Reflects the company's use of equity incentives as part of its compensation strategy to attract and retain key talent.

Next Steps

• The restricted stock units will vest according to the terms and schedule outlined in the Issuer's 2024 Equity Incentive Plan.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new operational or financial performance data that would significantly alter an investment thesis, thus a 'hold' recommendation is appropriate as it maintains existing sentiment.

Keywords

Artiva Biotherapeutics, ARTV, Subhashis Banerjee, Chief Medical Officer, RSU, Restricted Stock Units, Equity Incentive Plan, Insider Transaction, Form 4, Stock Grant